Scientists Use CRISPR-Cas9 to Create Red-Eyed Mutant Wasps – Sci-News.com
Sci-News.com |
Scientists Use CRISPR-Cas9 to Create Red-Eyed Mutant Wasps
Sci-News.com The red-eyed wasps were created to prove that CRISPR gene-slicing technology can be used on the tiny jewel wasp Nasonia vitripennis, giving scientists a new way to study some of the wasp’s biology. “No one knows how that selfish genetic element in some … Scientists ‘breed’ terrifying red-eyed mutant wasps…because they canWired.co.uk Wasp with red eyes created in labThe Hans India |
PR Newswire (press release) |
NYU Langone Research Leads to Accelerated Approval of Bladder …
PR Newswire (press release) NEW YORK, April 20, 2017 /PRNewswire-USNewswire/ — Findings from a clinical trial led by a researcher at NYU Langone’s Perlmutter Cancer Center helped … |
Regulatory Focus |
Regulatory Recon: Uniqure to Abandon Gene Therapy in EU; Pfizer Subpoenaed Over Saline Shortages (20 April 2017)
Regulatory Focus Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. Want to read Recon as soon as it’s posted? Follow @RAPSorg on Twitter. In Focus: US. The High Cost of Prescription Drugs in the United States (JAMA); HHS to … |
FiercePharma |
The world’s most pricey drugs, from a $1.2M gene therapy to a $450K lymphoma med
FiercePharma It’s a gene therapy, the first to win a regulatory nod, and on the leading edge of a potential wave of therapies of that ilk, many costing upwards of $1 million or more. Payers and other experts, worried about their advent, have been tossing around … |
|
ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting
Yahoo Finance REDWOOD CITY, Calif., April 20, 2017 /PRNewswire/ — ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that five abstracts with clinical data on the Company’s lead investigational immuno-oncology drug AM0010 … |
|
ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting
Yahoo Finance REDWOOD CITY, Calif., April 20, 2017 /PRNewswire/ — ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that five abstracts with clinical data on the Company’s lead investigational immuno-oncology drug AM0010 … |